Obizur    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
288自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)]2

288. 自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)] [臨床試験数:189,薬物数:219(DrugBank:29),標的遺伝子数:18,標的パスウェイ数:26
Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 189 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03199794
(ClinicalTrials.gov)
December 14, 201623/6/2017Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life PracticeProspective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life PracticeAcquired Hemophilia ABiological: OBIZURBaxalta now part of ShireBaxalta Innovations GmbH, now part of ShireRecruiting18 YearsN/AAll50United States;Austria;France;Germany;Italy;Netherlands;United Kingdom
2NCT02610127
(ClinicalTrials.gov)
December 30, 201529/10/2015Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia APost-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia AAcquired Hemophilia ABiological: OBIZURBaxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompleted18 YearsN/AAll53United States